{"id":"W2316810850","doi":"10.1158/1535-7163.targ-09-a105","title":"Abstract A105: Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: Associations of response by CT or DCE-MRI with patient outcome","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Hazard ratio; Oncology; Internal medicine; Hepatocellular carcinoma; Progression-free survival; Cancer; Clinical trial; Lung cancer; Phases of clinical research; Sorafenib; Interim analysis; Nuclear medicine; Urology; Overall survival; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000415103,0.000303828,0.0009081946,0.0001714431,0.00005674615,0.00001550351,0.0000981653,0.0001003355,0.00005904682],"category_scores_gemma":[0.00003242735,0.0002275872,0.0001587032,0.0003695611,0.00006043189,0.00006336944,0.00001462792,0.0002129293,3.887308e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003821529,"about_ca_system_score_gemma":0.0008163193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006937346,"about_ca_topic_score_gemma":0.000189243,"domain_scores_codex":[0.9977583,0.0001584005,0.001022629,0.0003638561,0.0003763877,0.0003204411],"domain_scores_gemma":[0.9982819,0.0002098024,0.0008126704,0.0003425395,0.0002212016,0.0001318843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009901267,0.002817901,0.07072172,0.0003069842,0.000822171,0.0002348281,0.003079413,0.001733972,0.8875824,0.000007171383,0.0001347101,0.02265747],"study_design_scores_gemma":[0.03259267,0.004201859,0.03325966,0.0006349202,0.002501364,0.000006239552,0.000418839,0.0008917988,0.9214692,0.0000270102,0.003505579,0.0004908316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843575,0.01120736,0.0007492136,0.00089958,0.00008113099,0.001663762,0.0008335457,0.00001972565,0.0001882132],"genre_scores_gemma":[0.994891,0.001780585,0.001862903,0.0009004301,0.00001783529,0.0001642365,0.00009414875,0.00004599804,0.0002428068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03746206,"threshold_uncertainty_score":0.9280735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03472244194285886,"score_gpt":0.3741749619326415,"score_spread":0.3394525199897827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}